Blockade of calcium channels and AT1 receptors prevents the hypertensive effect of calcilytic NPS 2143 in rats

• Autorzy: Rybczynska A. , Jurska-Jasko A. , Boblewski K. , Lehmann A. , Orlewska C.
• Języki publikacji: EN

Abstrakty

EN

Calcilytics, antagonists of calcium receptor, decrease sensitivity of this receptor to plasma calcium concentration and increase parathyroid hormone (PTH) secretion. Moreover, it was recently indicated that calcilytic NPS 2143 induces hypertension in rats. This study tested whether the increase of mean arterial blood pressure (MAP) induced by NPS 2143 administration is mediated by calcium channel and angiotensin II type1 (AT1) receptor activity. Wistar rats were anaesthesized with Thiopental i.p. and infused i.v. with saline supplemented with the anaesthetic. Blood pressure was monitored continuously in the carotid artery. Effects of NPS 2143 administered i.v. as bolus on MAP in the presence and absence of felodypine and losartan were investigated. Both, felodipine and losartan pretreatment provoked a persistent MAP decrease by 18±3 and 14±3 mmHg, respectively. Infusion of NPS 2143 at 1 mg/kg b.w. confirmed hypertensive activity of calcilytic and increased blood pressure for 21±4 mmHg. In contrast, administration of NPS 2143 in felodipine as well as in losartan pretreated rats did not change MAP as compared to felodipine/control and losartan/control groups, respectively. Our study indicated that both the blockade of calcium channels and the AT1 receptor activity prevented the hypertensive effect of calcilytic NPS 2143. This finding might be particularly important in understanding the mechanisms that mediated blood pressure changes related to the activity of calcium receptor.

Słowa kluczowe

EN

AT1 receptor; angiotensin II; arterial blood pressure; blockade; blood pressure; calcium channel; calcium receptor; felodipine; hypertension; losartan; parathyroid hormone; rat

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 2
• Opis fizyczny: p.163-170,fig.,ref.

Twórcy

autor

Rybczynska A.

• Medical University of Gdansk, 15 Tuwima Street, 80-210 Gdansk, Poland

autor

Jurska-Jasko A.

autor

Boblewski K.

autor

Lehmann A.

autor

Orlewska C.

Bibliografia

• Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+ sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
• Fox J, Lowe SH, Petty BA, et al. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290: 473-479.
• Nemeth EF, Bennet SA. Tricking the parathyroid glands with novel calcimimetic agents. Nephrol Dial Transplant 1999; 13: 1923-1925.
• Nemeth EF, DelMar EG, Heaton WL, et al. Calcylitics compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther 2001; 299: 323-331.
• Rybczynska A, Boblewski K, Lehmann A, et al. Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am J Hypertens 2005; 18: 364-371.
• Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-445.
• Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105: 1595-1604.
• Rybczynska A, Lehmann A, Jurska-Jasko A, et al. Hypertensive effect of calcilytic NPS 2143 in rats. J Endocrinol 2006; 191: 189-195.
• Allen AM, Zhuo J, Mendelsohn F. Localization and function of angiotensin AT1 receptors. Am J Hypertens 2000; 13: 31S-38S.
• Karaki H, Ozaki H, Hori M, et al. Calcium movements, distribution, and functions in smooth muscle. J Physiol 1997; 492: 61-74.
• Yamakage M, Namiki A. Calcium channels - basic aspects of their structure, function and gene encoding; anesthetic action on the channels - a review. Can J Anesth 2002; 49: 151-164.
• van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens 1993; 11: 3-11.
• DelMar EG, Barmore RM, Sheehan D, et al. Calcilytic compounds. US Patent 2003; 6: 521-667.
• Jirgensons A, Kauss V, Kalvinsh I, et al. A practical synthesis of tert-alkyloamines via the Ritter reaction with chloroacetonitrile. Synthesis 2000; 1709-1712.
• Lewanczuk RZ, Resnik LM, Ho MS, et al. Clinical aspects of parathyroid hypertensive factor. J Hypertens 1994; 12: 11-16.
• Lewanczuk RZ, Pang PKT. Vascular and calcemic effects of plasma of spontaneously hypertensive rats. Am J Hypertens 1990; 3: 189S-194S.
• Schluter, H., Kluth B, Borjesson-Stoll R, et al. Partial purification and characterization of a circulating hypertensive factor in spontaneously hypertensive rats. Eur J Biochem 1993; 218: 67-73.
• Lewanczuk RZ, Wang J, Zhang ZR, et al. Effects of spontaneously hypertensive rat plasma on blood pressure and tail artery calcium uptake in normotensive rats. Am J Hypertens 1989; 2: 26-31.
• Liang GH, Park S, Kim JA, et al. Stimalation of large-conductance Ca2+-activated K+ channels by the Na+/Ca2+ exchanger inhibitor dichlorobenzamil in cultured human umbilical vein endothelial cells and mouse aortic smooth muscle cells. J Physiol Pharmacol 2009; 60(1): 43-50.
• Ren J, Zhang L, Benishin CG. Parathyroid hypertensive factor inhibits voltage-gated K+ channels in vascular smooth muscle cells. Can J Physiol Pharmacol 1999; 77(11): 860-865.
• Louhelainen M, Merasto S, Fickenberg P, et al. Effects of calcium sensitizer OR-1986 on cardiovascular mortality and myocardial remodeling in hypertensive Dahl/Rapp rats. J Physiol Pharmacol 2009; 60(3): 41-47.
• Bottari SP, de Gasparo M, Steckelings M. Angiotensin II receptor subtypes: characterization, signaling mechanisms and possible physiological implications. Front Neuroendocrinol 1993; 14: 123-171.
• Baksi SN. Hypotensive action of parathyroid hormone in hypoparathyroid and hyperparathyroid rats. Hypertesion 1988; 11: 509-513.
• Pang PKT, Tenner TE Jr, Yee JA, et al. Hypotensive action of parathyroid hormone preparations on rats and dogs. PNAS 1980; 77: 675-678.
• Saglikes Y, Massry SG, Iseki K, et al. Effect of PTH on blood pressure and response to vascular agonist. Am J Physiol 1985; 248: F674-F681.
• Ziegelstein RC, Xiong Y, He C, et al. Expression of functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 2006; 342: 153-163.
• Tfelt-Hansen J, Hansen JL, Smajilovic S, et al. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes. Am J Physiol 2006; 290: H1165-H1171.
• Ohanian J, Gatfield KM, Ward DT, et al. Evidence for a functional calcium-sensing recptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol 2005; 288: H1756-H1762.
• Smajilovic S, Hansen JL, Christoffersen TE. Extra cellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 2006; 348: 1215-1223.
• Farzaneh-Far A, Proudfoot D, Weisberg PL, et al. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-40.
• Wonnenberger K, Scofield MA, Wangemann P. Evidence for a calcium-sensing receptor in the vascular smooth muscle cells of a spiral mediolar artery. J Membr Biol 2000; 175: 203-212.
• Smajilovic S, Sheykhzade M, Holmegard HN, et al. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul Pharmacol 2007; 47: 222-228.